Under construction – not a live service
Sign in
Taking peopleNo phase

Safety and Feasibility of TWIICE Rise - Phase 2

Key facts

Who runs it
TWIICE
Where
Switzerland1 site in 1 countryChoose a country to see its sites
Trial code
Status
Recruiting
People taking part
15 people, planned
Started
25 Jul 2023
Expected to end
31 Jul 2027
Type of study
Interventional
Treatments tested
  • TWIICE Rise
Record updated
10 March 2026

Who can take part

Age
18 years to 70 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 30 criteriaShow less

Who can take part

  • Informed Consent signed by the subject
  • Traumatic and non-traumatic SCI
  • Motor incomplete SCI with Neurological Level of Injury (NLI) C5-L5, or Motor Complete SCI with NLI T1-L5 as determined by the ISNCSCI
  • Male and non-pregnant, non-lactating female aged 18 to 70 years old
  • At least 6 months after injury
  • Able to stand or maintain upright position with a standing device (e.g., 'Easy stand') for at least ten minutes without clinical symptoms of orthostatic hypotension
  • Able to use crutches
  • Able to sit with knees and hips >= 90° flexion
  • Phase 1: Height of 160 to 180 cm, Phase 2: Height of 160 to 190 cm
  • Phase 1: Weight of <80 kg, Phase 2: Weight of <100 kg

Who cannot take part

  • Severe concurrent medical disease, illness, or condition
  • Individuals with a pacemaker, defibrillator, drug delivery pump, or other electrical devices if malfunctions could lead to serious adverse events
  • History of severe neurological injuries other than spinal cord injury (e.g., Multiple Sclerosis, Cerebral Palsy, Amyotrophic Lateral Sclerosis, Traumatic Brain Injury, Stroke)
  • Systemic or peripheral infection influencing wearing an exoskeleton
  • Diagnosis of coronary artery disease that precludes moderate to intense exercise
  • A medical diagnosis in the patient chart of atherosclerosis, congestive heart failure, or history of myocardial infarction
  • Untreated sever hypertension (systolic blood pressure >180 mmHg, diastolic blood pressure >120 mmHg)
  • History of lower extremities or pelvic fragility fractures within the last two years
  • Current pressure ulcer of the arms, trunk, pelvic area, or lower extremities
  • Psychiatric or cognitive conditions that may interfere with the trial
  • Other severe illness that the study physician considers in his/her clinical judgment to be exclusionary
  • Ability to walk 10 meters without physical assistance of a person
  • Deep vein thromboses in lower extremities of less than 6 months duration
  • Unstable spine or unhealed limbs
  • Heterotopic ossification that impairs joint mobility
  • Significant contractures defined as flexion contracture limited to 20 the hip and knee
  • Severe spasticity (Modified Ashworth grade 4) or uncontrolled clonus
  • Diagnosis of severe osteoporosis/penia: Dual Energy X-ray Absorptiometry (DXA) results indicating a t-score below -3.5 at the femoral neck or the total proximal femur bone, and knee bone mineral density (BMD) < 0.60 gm/cm2
  • Pregnancy or women who plan to become pregnant during the study period, and lactating women
  • Patient is currently involved in any other interventional study

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 70 years old?

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

The aim of this study is to assess the safety and the feasibility of two versions of TWIICE Rise for exoskeleton-assisted ambulation in patients with a spinal cord injury.

Read full original descriptionShow less

This study is done in two phases:

The first phase evaluates the safety and feasibility of TWIICE Rise 0.0 with 5 patients over 6 sessions in clinic. The second phase is being conducted with TWIICE Rise 1.0. This version has potentially improved functionalities based on feedback from Phase 1. Safety and feasibility will be assessed with 10 patients over 10 sessions in different settings (clinic, home, and community environment).

The group in the trial

  • Exoskeleton assisted ambulationTreatment being tested

    Phase 1: Five participants will undergo a training programme with the TWIICE Rise 0.0 two times a week for up to 6 weeks for a total of 6 sessions. Phase 2: Ten participants will undergo a training programme with the TWIICE Rise 1.0 2-3 times a week for up to 10 weeks for a total of 10 sessions.

    Treatment: TWIICE Rise

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
Two-phase Pilot Study on the Safety and Feasibility of TWIICE Rise for Exoskeleton-assisted Ambulation in Patients With Spinal Cord Injury
Fit questions
Built from NCT07461259, who can take part
Record updated
10 March 2026